• Corpus ID: 23773927

Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies.

  title={Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies.},
  author={Datshana Prakesh Naidoo and P. Sareli and Francisco Mar{\'i}n and Gustavo Aroca-Mart{\'i}nez and Frans. J. Maritz and Paulo C{\'e}sar Brand{\~a}o Veiga Jardim and Andr{\'e}s Ahuad Guerrero and Charles A Thompson and T Ber{\'o} and J Dr{\'a}zka and Viera Kosmalova and Thomas Dumortier and R. D. Smith},
  journal={Advances in therapy},
  volume={16 5},
The efficacy and tolerability of losartan 100 mg/hydrochlorothiazide (HCTZ) 25 mg and enalapril 10 mg/HCTZ 25 mg were compared in a double-blind, randomized trial in hypertensive patients inadequately controlled and experiencing side effects on prior therapy. Patients with moderate or severe hypertension, currently treated with at least two single-agent drugs (excluding angiotensin-converting enzyme inhibitors), with a sitting diastolic blood pressure (DBP) above 90 mm Hg, and at least one… 
Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy
Switching Asian patients currently not at BP goal with ARB or ACEI monotherapy to a losartan/HCTZ combination achieved BP goal in the majority of patients and were generally well tolerated.
Pharmacokinetics, Safety, and Antihypertensive Efficacy of Losartan in Combination with Hydrochlorothiazide in Hypertensive Patients with Renal Impairment
The combination of losartan/hydrochlorothiazide was effective in lowering blood pressure and was well tolerated in patients with mild to moderate renal impairment and safety was assessed in both studies by the incidence of adverse experiences.
Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide
Treatment of hypertensive patients with fixed-dose combination therapy consisting of the angiotensin II receptor blocker losartan along with hydrochlorothiazide (HCTZ) has several potential benefits over monotherapy with each individual component.
Efficacy and safety of losartan 100 mg or losartan 100 mg plus hydrochlorothiazide 25 mg in the treatment of patients with essential arterial hypertension and CV risk factors: obser-vational, prospective study in primary care
The BP lowering effect was similar in subgroups by treatment or comorbidity, respectively, however target attainment rates were substantially higher in non-diabetic patients and physicians reported somewhat lower target values than those stipulated by the guidelines.
A New Fixed-Dose Combination for Added Blood Pressure Control: Telmisartan Plus Hydrochlorothiazide
Telmisartan/hydrochlorothiazide provides additional anti-hypertensive efficacy compared with the respective monotherapies in a wide range of patients, including black patients, requires once-daily dosing, is cost-effective, well tolerated and is associated with less potassium depletion than hydrochloroth Diazide administered alone.
Trough-to-Peak Ratio, Smoothness Index, and Circadian Blood Pressure Profile After Treatment With Once-Daily Fixed Combination of Losartan 100 and Hydrochlorothiazide 25 in Essential Hypertension
The once-daily fixed combination of losartan 100 mg/hydrochlorothiazide 25 mg was evaluated for safety and efficacy in a multicenter open study by using 24-h ambulatory blood pressure monitoring in
Losartan/HCTZ remains an important option in the treatment of hypertension, as well as being indicated to reduce stroke risk in patients with hypertension and LVH.
Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension
There is insufficient weight of evidence to allow definitive conclusions to be drawn regarding the comparative efficacy of the available ARBs, however, newer ARBs appear to be more effective than older ARBs in reducing DBP and/or SBP in some trials.